Linear Clinical to conduct study of Covid-19 vaccine candidate
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials - The Lancet Infectious Diseases
Clover and Dynavax initiate dosing in Covid-19 vaccine candidate trial
Clover Biopharmaceuticals | Science | Trimer-Tag™
Clover Biopharmaceuticals | Science | Trimer-Tag™
Clover Biopharmaceuticals | Home
Clover Biopharmaceuticals starts construction of new R&D center in Shanghai
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications
Clover Biopharmaceuticals | Home
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications
Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients | Business Wire
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications